- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02398500
Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration
An Open-label Single Ascending Dose and Randomized Double-Masked, Ranibizumab Controlled, Safety, Tolerability, and Efficacy Study of Intravitreal LMG324 in Subjects With Neovascular Age-Related Macular Degeneration
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
The study will start with a single dose ascending (SAD) phase. LMG324 will be administered on Day 1 with no further treatment until implementation of standard of care (SoC) therapy. SoC therapy is ranibizumab 0.5 mg administered per label. Dose groups will be implemented sequentially to allow for safety review between the current and subsequent dose group. All treatments will be open-label, including ranibizumab used as SoC therapy.
In the enrollment expansion phase, subjects randomized to LMG324 arm will receive a single LMG324 IVT injection on Day 1 followed by sham (fake) IVT injections until implementation of SoC therapy. After implementation, SoC therapy will be applied monthly with sham injections applied at the interim planned visits. The enrollment expansion phase may start at a selected dose level whilst the dose escalation phase is still ongoing.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Texas
-
Fort Worth, Texas, Verenigde Staten, 76134
- Call Alcon Call Center for Trial Locations
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Must give written informed consent, be able to make the required study visits and follow instructions.
- Best corrected visual acuity (BCVA) of 34 letters (approximately 20/200 Snellen or better) in the non-study eye.
SAD population only:
- Subject's study eye must have a choroidal neovascularization (CNV) lesion due to age-related macular degeneration (AMD), either treatment naïve or previously treated, that can be expected to benefit, in the opinion of the investigator, from anti-vascular endothelial growth factor (anti-VEGF) therapy.
- Previously treated eyes must have a history of least 3 administrations of any intravitreal (IVT) anti-VEGF therapeutic for the treatment of CNV with the last injection administered ≥ 1 month prior to the planned administration of the study drug.
Enrollment expansion population only
- Subject's study eye must have untreated and active CNV lesion due to AMD.
- BCVA, between 73 - 23 letters, inclusive (approximate Snellen equivalent 20/40 - 20/320) in the study eye.
Exclusion Criteria:
SAD and enrollment expansion population
- Both eyes: any active ocular or periocular infection or active intraocular inflammation (eg, infectious blepharitis, infectious conjunctivitis, keratitis, scleritis, endophthalmitis).
- Study eye: current vitreous hemorrhage or a history of rhegmatogenous retinal detachment.
- Study eye: uncontrolled glaucoma (intraocular pressure [IOP] >25 mmHg on medication or according to Investigator's judgment).
SAD population only
- Presence of any contraindications, in the Investigator's opinion, to IVT anti-VEGF therapeutic administration.
Enrollment expansion population only
- Study eye: subject has received any approved or investigational treatment for exudative (wet) AMD other than vitamin supplements.
- Study eye: any current or history of macular or retinal disease other than exudative AMD
- Study eye: serous pigment epithelial detachment (PED) under the foveal center or retinal pigment epithelium (RPE) tear/rip.
- Study eye: any concurrent intraocular condition (eg, cataract, diabetic retinopathy) that, in the opinion of the Investigator, could either require medical or surgical intervention during the course of the study.
- Study eye: other ocular diseases that, in the opinion of the Investigator, can compromise the visual acuity
- Study eye: Surgery, as specified in the protocol.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: LMG324
SAD: LMG324 administered as a single IVT injection in 1 eye (study eye) in 1 of 4 doses, with 15-day follow-up
|
IVT injection
|
Experimenteel: LMG324 + sham
Expansion: LMG324 administered as a single IVT injection in 1 eye (study eye), followed by sham injections, until implementation of SoC therapy as specified in the protocol, for 24 weeks
|
IVT injection
Fake injection used for masking purposes
|
Actieve vergelijker: Lucentis + sham
Expansion: Ranibizumab 0.5 mg administered as monthly IVT injections in 1 eye (study eye) with interim sham injections, for 24 weeks
|
Fake injection used for masking purposes
IVT injection
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Mean change from baseline in best corrected visual acuity (BCVA) at Day 85
Tijdsspanne: Baseline, Day 85
|
Baseline, Day 85
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Percentage of LMG324-treated subjects with no identified SoC treatment need up to and including Day 85
Tijdsspanne: Up to Day 85
|
Up to Day 85
|
Best Corrected Visual Acuity (BCVA)
Tijdsspanne: Up to Day 169
|
Up to Day 169
|
Central subfield thickness total (CSFTtot)
Tijdsspanne: Up to Day 169
|
Up to Day 169
|
Central subfield thickness neuro-retina (CFSTnr)
Tijdsspanne: Up to Day 169
|
Up to Day 169
|
Lesion thickness
Tijdsspanne: Up to Day 169
|
Up to Day 169
|
Subretinal fluid with foveal involvement (SRFfi) thickness
Tijdsspanne: Up to Day 169
|
Up to Day 169
|
Retinal pigment epithelial detachment with foveal involvement (PEDfi) thickness
Tijdsspanne: Up to Day 169
|
Up to Day 169
|
Area of lesion (associated with CNV)
Tijdsspanne: Up to Day 169
|
Up to Day 169
|
Area of CNV within a lesion
Tijdsspanne: Up to Day 169
|
Up to Day 169
|
Area under the plasma concentration-time curve from time zero to infinity (AUCinf)
Tijdsspanne: Up to Day 169
|
Up to Day 169
|
Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)
Tijdsspanne: Up to Day 169
|
Up to Day 169
|
Area under the plasma concentration-time curve from time zero to time 't' where t is a defined time point after administration (AUC0-t)
Tijdsspanne: Up to Day 169
|
Up to Day 169
|
Maximum observed maximum plasma concentration (Cmax)
Tijdsspanne: Up to Day 169
|
Up to Day 169
|
Time to reach the maximum observed plasma concentration (Tmax)
Tijdsspanne: Up to Day 169
|
Up to Day 169
|
Observed maximum plasma concentration following drug administration, by dose (Cmax/D)
Tijdsspanne: Up to Day 169
|
Up to Day 169
|
Area under the plasma concentration-time curve divided by dose (AUC/D)
Tijdsspanne: Up to Day 169
|
Up to Day 169
|
Frequency of subjects with anti-LMG324 antibodies
Tijdsspanne: Up to Day 169
|
Up to Day 169
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie directeur: Clinical Scientist I, NIBR, Alcon Research
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- LMG324-2201
- 2014-005214-37 (EudraCT-nummer)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .